---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-051002"
form_type: "8-K"
ticker: "XWEL"
cik: "0001410428"
company_name: "XWELL, Inc."
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-20T23:51:20.556331+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years

## Summary
- Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.
- Cost of sales down 6% to $5.7M; operating expenses down 11% to $4.5M; operating loss $3.2M.
- Closed $4M private placement (Series G preferred + warrants) in Jan 2025; cash $3.7M, marketable securities $7.3M, no debt.
- Secured 3-year extension of CDC Traveler-based Genomic Surveillance Program (TGS) in March 2025.
- Plans to acquire medical spas in Orlando, Dallas, Salt Lake City; new XWELL location at NYC Penn Station mid-2025.

## SEC filing metadata
- accession: 0001104659-25-051002
- form_type: 8-K
- ticker: XWEL
- cik: 0001410428
- company_name: XWELL, Inc.
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/0001104659-25-051002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/tm2515209d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-051002
- JSON: https://secwatch.observer/filing/0001104659-25-051002.json
- Plain text: https://secwatch.observer/filing/0001104659-25-051002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.